UP!
AxoGen is a human tissue company based in Alachua, Florida making products to remedy peripheral nerve damage. In 2013 the company raised $18 million in its Initial Public Offering (IPO). AxoGen uses a cell graft technology AVANCE to mimic a human nerve. The company reports recovery in 87 percent of patients with peripheral nerve injuries. AxoGen is part of the Sid Martin Biotechnology Incubator.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-01 | Future report Set alerts | |
| Q2 2022 | 2022-08-03 | -0.06 | -0.06 |
| Q1 2022 | 2022-05-04 | -0.20 | -0.20 |
| Q4 2021 | 2022-02-22 | -0.08 | -0.08 |
| Q3 2021 | 2021-11-03 | -0.09 | -0.09 |
| Q2 2021 | 2021-08-04 | -0.09 | -0.09 |
| Q1 2021 | 2021-05-05 | -0.08 | -0.08 |
| Q4 2020 | 2021-02-22 | -0.08 | -0.08 |
| Q3 2020 | 2020-10-29 | 0.04 | 0.04 |
| Q2 2020 | 2020-08-05 | -0.15 | -0.15 |
| 2016-05-05 | Reiterated Rating | Wedbush | Outperform | $7.50 |
| 2016-03-01 | Reiterated Rating | Wedbush | Outperform | $7.50 |
| 2015-11-06 | Boost Price Target | Wedbush | $5.00 to $7.50 | |
| 2015-11-06 | Boost Price Target | JMP Securities | Market Outperform | $5.50 to $8.00 |
| 2015-08-27 | Reiterated Rating | Wedbush | Outperform | $5.00 |
| 2015-04-01 | Downgrade | Langenberg & Company | Hold | |
| 2015-04-01 | Downgrade | Ladenburg Thalmann | Buy to Neutral | $5.50 to $3.75 |
| 2015-03-12 | Initiated Coverage | Wedbush | Outperform | $5.00 |
| 2014-11-26 | Initiated Coverage | Lake Street Capital | Buy | |
| 2014-11-25 | Initiated Coverage | Lake Street Capital | Buy | $4.00 |
| 2014-05-14 | Initiated Coverage | Dawson James | Buy | $5.00 |
| 2013-10-31 | Boost Price Target | Ladenburg Thalmann | Buy | $4.50 to $5.75 |
| 2016-05-05 | Reiterated Rating | Wedbush | Outperform | $7.50 |
| 2016-03-01 | Reiterated Rating | Wedbush | Outperform | $7.50 |
| 2015-11-06 | Boost Price Target | Wedbush | $5.00 to $7.50 | |
| 2015-11-06 | Boost Price Target | JMP Securities | Market Outperform | $5.50 to $8.00 |
| 2015-08-27 | Reiterated Rating | Wedbush | Outperform | $5.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AXGN 108 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Arrowpoint Asset Management, LLC | 4.84M |
| First Light Asset Management, LLC | 2.91M |
| BlackRock Inc. | 2.91M |
| Point72 Asset Management, L.P. | 2.16M |
| Vanguard Group, Inc | 1.91M |
| BANK OF AMERICA CORP /DE/ | 1.84M |
| HENDERSON GROUP PLC | 1.38M |
| PERCEPTIVE ADVISORS LLC | 0.95M |
| STATE STREET CORP | 0.84M |
| BlackRock Fund Advisors | 0.83M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.74M |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 0.69M |
| D. E. Shaw & Co., Inc. | 0.66M |
| Granite Investment Partners, LLC | 0.54M |
| MORGAN STANLEY | 0.53M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Essex Woodlands Fund IX, L.P. | 21.25% (3711111) | AXGN / PSDV / |
| NEELS GUIDO J | 19.30% (3371111) | AXGN / ELGX / |
| Flynn James E Possible Member of 10% Group | 17.18% (3000000) | AAVL / ALIM / ASPX / ATRS / AUXL / AXGN / CASM / CYCC / DRNA / EHTH / EMAG / FIXX / HITK / LOXO / NURO / PRTO / REPH / RIGL / STRM / TRGT / TWTI / VNDA / XNPT / |
| Mandato Joseph M | 7.02% (1226773) | AXGN / |
| Hopfenspirger Larry | 2.44% (426066) | AXGN / |
| Gold Mark Stephen | 2.06% (360248) | AXGN / |
| Zaderej Karen L. Chief Executive Officer | 1.62% (282147) | AXGN / |
| Harper John Frederick | 1.23% (214094) | AXGN / |
| Freitag Gregory Gene CEO, CFO | 0.92% (160865) | AXGN / PBIO / |
| Hansen David K Corporate Controller | 0.25% (43792) | AXGN / |
| MCCARREY SHAWN F SVP of Sales | 0.25% (43057) | AXGN / |
| Donovan Michael Patrick Vice President, Operations | 0.22% (37617) | AXGN / |
| Johnston Lee Robert Jr Chief Financial Officer | 0.14% (25000) | AXGN / |
| Rudelius Robert James | 0.13% (23273) | AXGN / |
| Schiaparelli Jill F SVP, Bus. Strategy&Marketing | 0.07% (12750) | AXGN / |
| Friedman Mark Louis Vice President of RA/QA | 0.03% (5665) | AXGN / |
| DeVinney Erick Wayne See Remarks | 0.03% (4659) | AXGN / |
UM